Format

Send to

Choose Destination
Dig Liver Dis. 2015 Feb;47(2):138-43. doi: 10.1016/j.dld.2014.10.010. Epub 2014 Nov 8.

PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: perspectives in the diagnosis of pancreatic cancer.

Author information

1
Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ancona, Italy. Electronic address: m.marzioni@univpm.it.
2
Division of Gastroenterology, Azienda Ospedaliero Universitaria "Ospedali Riuniti", Ancona, Italy.
3
Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ancona, Italy.
4
Epidemiology Unit, Centro Studi Fegato, Trieste, Italy.
5
Servizio di Gastroenterologia - Ospedale "Ramazzini" Carpi, Modena, Italy.
6
Institute of Pathologic Anatomy, Università Politecnica delle Marche, Ancona, Italy.
7
Division of Cytopathology, Azienda Ospedaliero Universitaria "Ospedali Riuniti", Ancona, Italy.
8
Division of Gastroenterology and Digestive Endoscopy, Università degli Studi di Bologna, Castel San Pietro Terme Hospital, Castel San Pietro Terme, Italy.

Abstract

BACKGROUND AND AIMS:

Endoscopic ultrasound-guided fine needle aspiration is routinely used in the diagnostic work up of pancreatic cancer but has a low sensitivity. Studies showed that Pancreatic Duodenal Homeobox-1 (PDX-1) is expressed in pancreatic cancer, which is associated with a worse prognosis. We aimed to verify whether the assessment of PDX-1 in endoscopic ultrasound-guided fine needle aspiration samples may be helpful for the diagnosis of pancreatic cancer.

METHODS:

mRNA of 54 pancreatic cancer and 25 cystic lesions was extracted. PDX-1 expression was assessed by Real-Time PCR.

RESULTS:

In all but two patients with pancreatic cancer, PDX-1 was expressed and was found positive in 7 patients with pancreatic cancer in which cytology was negative. The positivity was associated with a probability of 0.98 (95% CI 0.90-1.00) of having cancer and the negativity with one of 0.08 (95% CI 0.01-0.27). The probability of cancer rose to 1.00 (95% CI 0.97-1.00) for patients positive to both PDX-1 and cytology and fell to 0.0 (95% CI 0.00-0.15) in patients negative for both.

CONCLUSIONS:

PDX-1mRNA is detectable in samples of pancreatic cancer. Its quantification may be helpful to improve the diagnosis of pancreatic cancer.

KEYWORDS:

EUS; FNA; PDX-1; Pancreatic cancer; Sensitivity; Specificity

PMID:
25454709
DOI:
10.1016/j.dld.2014.10.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center